J Immunother Cancer, 2022, 10(6)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors

Both ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2 ADCs against solid tumors. This is the first study to analyze cytotoxic activity of clinically relevant anti-GD2 ADCs in a wide panel of cell lines with varying GD2 expression and their effects in mouse models of GD2-positive solid cancer.

Kalinovsky DV, Kibardin AV, Kholodenko IV, Svirshchevskaya EV, Doronin II, Konovalova MV, Grechikhina MV, Rozov FN, Larin SS, Deyev SM, Kholodenko RV

Department of immunology, Laboratory of cell interactions, Laboratory of molecular immunology

: 10.1136/jitc-2022-004646
Scopus: 2-s2.0-85133105214
: 35764367
IBCH: 10084
Ссылка на статью в журнале: https://doi.org/10.1136/jitc-2022-004646
Кол-во цитирований на 03.2024: 11
Данные статьи проверены модераторами 2022-07-18

Список научных проектов, где отмечена публикация

  1. -Органотипические модели опухолей с использованием микрофлюидных технологий (January 6, 2021 — December 31, 2024). Zvyagin A.V.. Grant, RSF.